We collected 14 patients who tested positive for nasopharyngeal swab real-time PCR for COVID-19 infections, in mild to moderate stage, among which are 6 males and 8 females with ages ranging from 30 to 77. The two control groups were 13 non-COVID-19 pneumonia patients and 10 healthy people. Then we applied a mass spectrometry-based, data-independent acquisition (DIA) quantitative proteomic approach to analyze urine samples from COVID-19 patients and controls. This allowed us to produce a comprehensive map of the molecular changes associated with early-stage COVID-19 infections.